Close Menu

Ah, the Promise

GlaxoSmithKline's CEO Andrew Witty says that overhauling the company's drug discovery operation was a "major upheaval" but is now showing results. According to Reuters, Witty also says that in the last 15 years, the drug industry floundered by basing the discovery process on combinatorial chemistry, genomics, and proteomics. "These were all supposed to transform productivity yet none of them did.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.